Teva Launches Generic Nexium
Teva Pharmaceuticals announced the launch of its generic version of Nexium (esomeprazole magnesium delayed-release capsules) which received U.S. FDA Approval on January 23, 2015. Nexium is a drug commonly used to treat gastroesophageal reflux (GERD), risk reduction of non-steroidal anti-inflammatory drug (NSAID)-associated gastric ulcers, Helicobacter pylori eradication to reduce the risk of duodenal ulcer recurrence and treatment of hypersecretory conditions (e.g. Zollinger-Ellison syndrome). The brand name Nexium is manufactured by AstraZeneca.
Teva was not granted 180 days of generic exclusivity. However, the U.S. Food and Drug Administration (FDA) has not yet granted final approval for other manufacturer’s generics to Nexium.
Teva will distribute its generic Nexium in 20 mg and 40 mg capsules.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.